<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576068</url>
  </required_header>
  <id_info>
    <org_study_id>2008/3128/I</org_study_id>
    <nct_id>NCT01576068</nct_id>
  </id_info>
  <brief_title>Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry</brief_title>
  <acronym>FARMAEPOC</acronym>
  <official_title>Efficiency of COPD Case Finding Program by Spirometry in High-risk Customers of Urban Community Pharmacies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Col·legi de Farmacèutics de la Província de Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Respiratory Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catalan Society of Family Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Col·legi de Farmacèutics de la Província de Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease. In the investigators
      country, underdiagnosis has been estimated in around 80% of subjects. Early detection is done
      mainly in primary care but due to actual situation new alternatives have been proposed to
      decrease underdiagnosis.

      This present study promote by a multidisciplinary research team (respiratory medicine,
      primary care, nurse and pharmacist) raise the objective of evaluate the effect of a COPD case
      finding program guide by spirometry in community-pharmacies.

      From the results of a pilot-study conducted in 13 community-pharmacies in Barcelona, in which
      the investigators showed the feasibility of spirometry in community-pharmacies for the early
      detection of COPD, the investigators have design a second phase to evaluate the effect of
      this strategy. 100 Barcelona's community-pharmacies during 6 months will select high risk
      customers and will conduct a spirometry in agreement with the design protocol. 3600
      spirometries is the establish objective. Participants hospitals will train pharmacist in
      spirometry and also control spirometry quality daily by a telematic pathway. Spirometry
      results will be evaluate in terms of effect and costs. The investigators will also evaluate
      the impact of this program in the health system by numbers of subjects diagnosed and follow
      up in primary care.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COPD Case Finding</measure>
    <time_frame>During 15 months pharmacies will include subjects with possible COPD through spirometry.</time_frame>
    <description>Proportion of high-risk customers with spirometry showing a FEV1/FVC under 0,7.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>High Risk Customers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pharmacy customers with GOLD COPD Criteria of high-risk subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation</description>
    <arm_group_label>High Risk Customers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 40 years.

          -  Current or former smoker

          -  Chronic respiratory symptoms(cough, shortness of breath, expectoration)

        Exclusion Criteria:

          -  Previous diagnosed chronic lung disease

          -  Use of inhalers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Castillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Col·legi Oficial de Farmacèutics de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Castillo D, Guayta R, Giner J, Burgos F, Capdevila C, Soriano JB, Barau M, Casan P; FARMAEPOC group. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study. Respir Med. 2009 Jun;103(6):839-45. doi: 10.1016/j.rmed.2008.12.022. Epub 2009 Feb 5.</citation>
    <PMID>19200706</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Pharmacy</keyword>
  <keyword>Spirometry</keyword>
  <keyword>Case finding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

